MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
CooperVision, Inc. · Decision date Oct 28, 2025
What did the FDA approve?
FDA records P180035/S031 as a supplement to PMA P180035, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Oct 28, 2025.
FDA approval order statement
Approval of protocol changes to enroll approximately 1000 subjects in PAS002 to achieve at least 4000 patient years total (approximately 2000 per study) with an average follow up of 2-3 years per subject. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P180035.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Ophthalmic
- Decision date
- Oct 28, 2025
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P180035/S031
- Regulatory pathway
- PMA supplement
- Applicant
- CooperVision, Inc.
- Product code
- QIT
- Decision code
- APPR
- Decision date
- Oct 28, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Daily wear soft contact lens to reduce the progression of myopia.
- Applicant
- CooperVision, Inc.
- Product code
- QIT
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P180035/S030 · Related supplement
MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
P180035/S031 received
Application receipt date recorded by FDA.
P180035/S031 · FDA decision
Normal 180 Day Track No User Fee
P180035/S032 · Related supplement
MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
P180035/S033 · Related supplement
MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
P180035/S034 · Related supplement
MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
Timeline entries are records held by MedtechLedger for P180035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| CooperVision, Inc. | PMA supplement | Jul 30, 2025 | FDA | |
| CooperVision, Inc. | PMA supplement | Dec 17, 2025 | FDA | |
| CooperVision, Inc. | PMA supplement | Dec 23, 2025 | FDA | |
| CooperVision, Inc. | PMA supplement | Feb 17, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
CooperVision, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5870 Stoneridge Dr., Suite 1, Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P180035/S031
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


